OCS OCULIS HOLDING AG

Oculis to Participate in Upcoming June Investor Conferences

Oculis to Participate in Upcoming June Investor Conferences

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:

Goldman Sachs Annual Healthcare Conference

June 9-11; Miami, FL, U.S.

Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET.

J.P. Morgan European Healthcare Conference  

June 12; London, U.K.

Riad Sherif, MD, Chief Executive Officer, will be attending.

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the  page under the Investors & Media section.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit:

Oculis Contacts

Ms. Sylvia Cheung, CFO

Investor Relations

LifeSci Advisors

Corey Davis, Ph.D.

Media Relations

ICR Healthcare

Amber Fennell / David Daley / Sean Leous



EN
03/06/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Results of 2025 Annual General Meeting

Oculis Publishes Results of 2025 Annual General Meeting ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.  The Company’s shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders ackn...

June 5, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir niðurstöður aðalfundar 2025

Oculis birtir niðurstöður aðalfundar 2025 ZUG, Sviss, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), tilkynnti í dag niðurstöður aðalfundar 2025 sem haldinn var 4. júní 2025 á Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Sviss, klukkan 13:00 að íslenskum tíma / 15:00 CEST / 09:00 EDT. Hluthafar félagsins samþykktu alla dagskrárliði. Hluthafar samþykktu ársreikning ársins 2024, þar á meðal lögbundin reikningsskil og samstæðureikning 2024. Hluthafar tóku til greina að á grundvelli lögbundinna reikningsskila var tap félagsins CHF 5.179...

June 5, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Results of 2025 Annual General Meeting

Oculis Publishes Results of 2025 Annual General Meeting ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company’s shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowl...

June 5, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments

June 3, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming June Investor Conferences

Oculis to Participate in Upcoming June Investor Conferences ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, U.S.Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET. J.P. Morga...

June 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch